At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 4,372 enrolled
Drug / intervention
clarithromycindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial
Copenhagen Trial Unit, Center for Clinical Intervention Research·interventional·Posted Jul 21, 2005·Updated Aug 11, 2016
In Brief
A Phase 3 clinical trial evaluating clarithromycin for Heart Disease and Cardiovascular Disease. Completed, enrolled 4,372 participants across 6 sites.
Detailed Summary
A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart disease. The purpose of this study is to determine the positive and negative effect of 14 days treatment with clarithromycin 500 mg daily in patients already suffering from stable coronary heart disease. The participants will be followed for at least two years after the treatment. Abbott Laboratories supplied Clarithromycin and placebo tablets.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Disease, Cardiovascular Disease
CountriesDenmark
Timeline
Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 1999
Primary CompletionApr 2000
Study CompletionSep 2002
First PostedJul 2005
TodayJul 2026
First PostedJul 21, 2005
Enrollment StartOct 1, 1999
Primary CompletionApr 1, 2000
Study CompletionSep 1, 2002
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.9 years ago
Interventions
clarithromycindrug